September 2013. Volume 9. Number 3

More than six doses of palivizumab are needed to prevent one episode of wheezing in late preterm infants

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al.; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-9.
Reviewers: Ochoa Sangrador C1, González de Dios J2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas@meditex.es
Reception date: 31/07/2013
Acceptance date: 04/08/2013
Publication date: 04/09/2013

Abstract

Authors' conclusions: in otherwise healthy late preterm infants, palivizumab treatment resulted in a significant reduction in wheezing days during the first year of life, even after the end of treatment. These findings implicate RSV infection as an important mechanism of recurrent wheeze during the first year of life in such infants.

Reviewers' commentary: we should know the clinical consequences of the avoided wheezing episodes before estimating the applicability of the results of this study in our clinical practice. This is because the cost of the proposed treatment is high and of course much higher than the treatment of these episodes (6.4 doses should be put to prevent one episode of wheezing). Finally, we also need to know whether prevention showed in the first year of life will last over time.

How to cite this article

Ochoa Sangrador C, González de Dios J. Para evitar un episodio de sibilancias en prematuros tardíos se requieren más de seis dosis de palivizumab. Evid Pediatr. 2013;9:42.

AVC | Critically appraised articles

Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al.; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-9.
Reviewers: Ochoa Sangrador C1, González de Dios J2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas@meditex.es
Reception date: 31/07/2013
Acceptance date: 04/08/2013
Publication date: 04/09/2013

How to cite this article

Ochoa Sangrador C, González de Dios J. Para evitar un episodio de sibilancias en prematuros tardíos se requieren más de seis dosis de palivizumab. Evid Pediatr. 2013;9:42.

References

  1. Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J. 2013;32:820-6.
  2. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-7.

Related Articles

CA | Involvement of respiratory syncytial virus in infant recurring bronchitis and possible prevention

Moral Gil L. Implicación del virus respiratorio sincitial en las bronquitis recurrentes del lactante y su posible prevención. Evid Pediatr. 2013;9:52.
04/09/2013

Linked Comment

CA | Involvement of respiratory syncytial virus in infant recurring bronchitis and possible prevention

Moral Gil L. Implicación del virus respiratorio sincitial en las bronquitis recurrentes del lactante y su posible prevención. Evid Pediatr. 2013;9:52.